XOMA (XOMA) 052 Clinical Results Support Novel Anti-Inflammatory Approach to Type 2 Diabetes Treatment
Tweet Send to a Friend
XOMA Ltd. (Nasdaq: XOMA) announced new results which included additional data for up to three months and new measures of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


